A day after Sanofi informed U.S. officials it was looking into reports of employees paying bribes in the Middle East, GlaxosmithKline said it was doing the same in the United Arab Emirates.
Valeant CEO J. Michael Pearson has said he's confident Allergan shareholders will vote in support of his company's hostile bid come December. But it never hurts to have a little insurance.
What's a drugmaker hauled up for marketing violations to do? If you're Galderma, you declare yourself exempt from the rules.
Last month, the feds took issue with Bayer's marketing for its Phillips' Colon Health product, saying the company's claims lacked scientific backing. But the way the German pharma sees it, the legal standard the DOJ is holding it to is not only unfair, it's unprecedented.
Now, it's Sanofi digging into potential bribery in the Middle East. The French drugmaker told U.S. officials that it's eyeing allegations from an anonymous whistleblower about improper payments from 2007 to 2012.
Allergan's still okay with holding a special shareholder meeting on Dec. 18, a date it last month agreed on with wannabe acquirer Valeant. It just doesn't want its pursuer's partner, Bill Ackman, to have a say.
A debate has raged over the past couple of years over whether world governments are wasting money by stockpiling Roche's Tamiflu and GlaxoSmithKline's Relenza to help combat a potential flu epidemic. At issue is a tough question: Are the drugs effective enough to justify the estimated $2 billion spent to stockpile them?
Gilead Sciences' hepatitis C drug Sovaldi may be worth the sticker price. But it's too expensive for the U.K.'s health system to bear. That's the assessment in some National Health Service documents obtained by the Health Service Journal.
Teva and Mylan merge? Rumors are certainly swirling--and not for the first time, either. But while a potential deal might make financial sense, at least one analyst doesn't see it happening.
Ever since Pascal Soriot took the reins at AstraZeneca, he's been talking up Brilinta as a diamond in the rough. With some work, the clot-fighting drug really could become a blockbuster, the CEO figures. No, really.
Endo Health Solutions tried hard to ward off generic competitors for its big-selling pain med Opana ER. For instance, it petitioned the FDA to block competitors on safety grounds. According to a new lawsuit, Endo also paid off generics maker--and potential rival--Impax Laboratories.
On "60 Minutes," Dr. Peter Bach and Leonard Saltz deliver some sound bites that might get the general public talking--and politicians, too.
Back in April, Sanofi CEO Chris Viehbacher said he planned to sell off some of the company's mature products to make room for higher-value "bolt-on" acquisitions. Rumors about potential buyers immediately started flying. Analysts estimated the drugs could fetch $8 billion or more.
Lawyers in another Actos failure-to-warn trial claimed the company put profits ahead of patient safety, by keeping mum on study data that flagged links between the diabetes drug and cancer.
Yet another drugmaker is taking a cheap drug and turning it into an FDA-approved brand--and adding an enormous premium along the way. Once again, the cost increase promises to be huge, The Street reports: Analysts figure on a list price of $60,000 to $80,000 per year.
It's a good time to be a specialty drugmaker--especially one looking to sell itself. And that's the position Arbor Pharmaceuticals is reportedly in right now.
One hospital chain has struck back at Roche's Genentech unit for switching its top 3 cancer treatments to specialty distributors. Ascension Health, a Roman Catholic-based group of more than 130 hospitals, is barring Genentech sales reps at the door.
Chalk up a victory for the U.S. Treasury Department, whose new rules put the kibosh on Salix Pharmaceuticals' tax inversion deal for Cosmo's Irish unit. Instead, the North Carolina company is reportedly in talks to sell itself--but to Actavis, not Allergan.
Roche just can't win with the U.K.'s drug price watchdog, the National Institute for Health and Care Excellence (NICE). In August, the agency decided the company's heralded breast cancer drug Kadcyla was too expensive for the country's health system to cover. Now NICE has slapped Roche with a preliminary thumbs-down on Gazyvaro, its new drug to treat chronic lymphocytic leukemia (CLL).
According to new research, Merck's investigational, 9-valent HPV vaccine has the potential to block about 90% of invasive cervical cancer cases worldwide. But realizing that potential will be no piece of cake.